Navigation Links
Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs
Date:7/23/2008

Study results pending publication in July print edition of Clinical

Chemistry, available on Web

INDIANAPOLIS, July 23 /PRNewswire/ -- A Roche Diagnostics-sponsored pilot study evaluating the use of N-terminal pro-B-type natriuretic peptide (NT-proBNP) confirms the potential value of NT-proBNP for risk stratification in predicting the risk of cardiovascular adverse events (CV-AE) in patients treated with non-steroidal anti-inflammatory drugs of the COX inhibitor class.

The complete results of the study, currently available at http://www.clinchem.org , are scheduled for publication in the July print edition of Clinical Chemistry.

Non-steroidal anti-inflammatory drugs (NSAIDs) -- for example, acetylsalicylic acid and ibuprofen -- are the best known inhibitors of COX (cyclo-oxygenase), an enzyme involved in the inflammation pathway. This inhibition provides relief from the symptoms of the inflammation process; for example, fever and pain.

These drugs are routinely used to treat patients with osteoarthritis, rheumatoid arthritis and other pathologies associated with inflammation. However, studies with newer NSAIDs such as the selective COX-2 inhibitors (also called coxibs) have resulted in concern that there might be an increase in the risk of heart attack, thrombosis or stroke associated with long-term, high-dosage use of coxibs. Traditional NSAIDs (tNSAIDs) demonstrate comparable risks in observational studies.

Cardiovascular risk could be predicted

A pilot study(1) examined whether the risk of CV-AE could be predicted by measuring the NT-proBNP concentration in patients taking anti-inflammatory drugs. Baseline samples were measured by Elecsys proBNP (Roche Diagnostics) in 433 patients with osteoarthritis of the knees, with or without osteoarthritis of the hands, during an observational period of 200 days.

Cardiovascular adverse events -
'/>"/>

SOURCE Roche Diagnostics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014 Apnea Sciences ( ... offices in Aliso Viejo , California.  ... to the tremendous growth and worldwide expansion, a new ... patented SnoreRx, the anti snore cure have exceeded our ... "We are now in 23 countries and will ...
(Date:12/22/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/hmlfbq/investment ) ... Analysis of the US Medical Device Sector " ... http://photos.prnewswire.com/prnh/20130307/600769 This analysis ... identifies the key trends and rationale for undertaking ... and acquisitions. The study will be ...
(Date:12/22/2014)... and STOCKHOLM , Dec. ... (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced that ... of the European Medicines Agency (EMA) has adopted a ... histolyticum) for the treatment of adult men with Peyronie,s ... at least 30 degrees at the start of therapy. ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
(Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch as ... coolest mobile applications on the iOS, Android, and Windows markets. ... conducted the app review and shared with viewers how this ... The old saying goes, “A picture says a thousand words.” ... describe a single image, because each picture holds a unique ...
(Date:12/25/2014)... 25, 2014 Parker & Sons, Inc. ... service and affordable quality regarding heating, cooling and plumbing ... in 2014 by the “Queen of Clean” for impressive ... an impressive reputation over the years for providing outstanding ... range of contractor services for both homeowners and businesses. ...
(Date:12/24/2014)... TX (PRWEB) December 24, 2014 Connie ... specialist and functional medicine advocate with 30 years of ... trial to evaluate the health benefits of dietary detoxification. ... with new participants following excellent results from test patients ... When asked to explain her interest in conducting the ...
(Date:12/24/2014)... 24, 2014 Dr. Vu Ho, a ... of his practice and med-spa with the addition of ... list of cosmetic treatments and services. , “Silk Peel ... skin,” says Dr. Ho. “As a result it can ... wrinkles, sun spots, discolorations or blemishes.” , Similar to ...
(Date:12/24/2014)... The report “Stivarga (Colorectal Cancer) – ... current treatment landscape, unmet needs, current pipeline and commercial ... drug which is used in the treatment of colon ... is also prescribed to patients who suffer from advanced ... is a multi-kinase inhibitor and it blocks many enzymes ...
Breaking Medicine News(10 mins):Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... molecules that are responsible for controlling genes that cause ... Memorial Sloan-Kettering Cancer Center (MSKCC), appears in the January ... inhibit the activity of entire sets of genes associated ... the majority of cancer-related deaths. The new work explains ...
... PRGO ; TASE) today announced that it has ... in Barnsley, Yorkshire,United Kingdom, privately-held Galpharm is a leading ... super,markets, drug stores and pharmacies in the U.K. The ... sales annually and be accretive to earnings,in the first ...
... Court Justice Antonin Scalia, FDA Commissioner Andrew C.,von ... FDLI/FDA,Meeting in Washington, D.C., WASHINGTON, Jan. 9 ... Conference, co-sponsored with the Food and Drug,Administration, will ... and food & drug law & regulation., ...
... Trial Begins this Week in Fort Worth, Texas in an ... Toxins in the Air,Destroying a Town, Hundreds of Residents ... Birth Defects, NEW YORK, Jan. 9 The first ... a railroad tie,factory poisoned residents in the small town of ...
... a quick fix to physical and mental ailments, psychoanalysts ... about the potential benefits and drawbacks of including medication ... The Uses of Medications in Psychoanalysis: What We Know; ... psychoanalyst Glen O. Gabbard, M.D., at the American Psychoanalytic ...
... Extract Released Just in Time for the Holiday ... ... The average American gains 50%,of his yearly weight gain during the Holiday ... overweight., Metabothin ( http://www.metabothin.net ), the herbal weight loss formula,from American ...
Cached Medicine News:Health News:Molecules can block breast cancer's ability to spread 2Health News:Perrigo Acquires UK OTC Store Brand Supplier 2Health News:51st Food and Drug Law Institute Annual Conference Focuses on Relationship Between Scientific Advances and FDA Law & Regulation 2Health News:51st Food and Drug Law Institute Annual Conference Focuses on Relationship Between Scientific Advances and FDA Law & Regulation 3Health News:Worse Than Love Canal - A Town Poisoned by Corporate Greed 2Health News:Uses of medications in psychoanalysis 2Health News:Metabothin B56 with Ephedra Extract Now Available 2
... Bard Collagen Implant, the world's leading bulking ... for the treatment of Stress Urinary Incontinence ... surrounding urethral tissue to aid coaptation in ... body's own structure, Contigen Bard Collagen Implant ...
... The Titan™ Inflatable Penile Prosthesis ... designed to be surgically implanted ... management of erectile dysfunction (also ... provides the patient with voluntary ...
... malleable penile prostheses offer easy-to-use, low-cost options ... These implants are always rigid, but their ... in an erect or concealed position. Designed ... sexual intercourse and to not interfere with ...
... The Alpha I continues to be ... show the Alpha I to have mechanical ... years on first-time implants. ioflex material contributes ... Alpha I. Thats because Bioflex: ,Provides maximum, ...
Medicine Products: